US20140066511A1 - Topical delivery of l-arginine to cause beneficial effects - Google Patents

Topical delivery of l-arginine to cause beneficial effects Download PDF

Info

Publication number
US20140066511A1
US20140066511A1 US14/067,219 US201314067219A US2014066511A1 US 20140066511 A1 US20140066511 A1 US 20140066511A1 US 201314067219 A US201314067219 A US 201314067219A US 2014066511 A1 US2014066511 A1 US 2014066511A1
Authority
US
United States
Prior art keywords
arginine
scalp
preparation
hair
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/067,219
Inventor
Eric T. Fossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strategic Science and Technologies LLC
Original Assignee
Strategic Science and Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strategic Science and Technologies LLC filed Critical Strategic Science and Technologies LLC
Priority to US14/067,219 priority Critical patent/US20140066511A1/en
Assigned to STRATEGIC SCIENCE & TECHNOLOGIES, LLC reassignment STRATEGIC SCIENCE & TECHNOLOGIES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOSSEL, ERIC THOR
Publication of US20140066511A1 publication Critical patent/US20140066511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Definitions

  • This invention relates to topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
  • substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
  • topical application of a nitric oxide precursor, L-arginine in its various forms contained in a variety of topical preparations, either by themselves or with other agents to aid in penetration, such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to the scalp causes hair growth, when administered to superficial ulcers causes healing and when administered to the penis enhances erectile function.
  • a penetrating cream containing L-arginine at an effective concentration and a salt, such as sodium chloride, at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to nightly to the scalp containing a deficit of hair induces hair growth within 3-4 months.
  • a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to the penis induces firm and natural erections within 20 minutes.
  • the delivery vehicle is a penetrating cream
  • the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption.
  • the preferred embodiment consists of a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (12.5% w/v), choline chloride (10%), sodium chloride (5% w/v) and magnesium chloride (5% w/v).
  • the components of the base cream may be those commonly found in hand creams, such as water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A & D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, and BHA.
  • L-arginine hydrochloride provides a precursor to the molecule, nitric oxide, NO.
  • Nitric oxide is the substance that relaxes the blood vessels, allowing for increased blood flow.
  • Choline chloride, sodium chloride and magnesium chloride provides a high ionic strength environment for the highly charged molecule, L-arginine.
  • This high ionic strength environment is an example of a hostile biophysical environment for L-arginine. That is, the highly charged ionic strength is an unfavorable environment for the highly charged L-arginine making the L-arginine anxious to move to a more hospitable, less charged environment such as human tissue.
  • the base cream containing L-arginine, choline chloride, sodium chloride and magnesium chloride is the agent which produces beneficial effects such as hair growth, healing of ulcers such as leg ulcers or restoration of normal erectile function in males suffering from erectile dysfunction.
  • the cream acts effectively to induce hair growth on human scalp lacking sufficient hair when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. Yet further, the cream acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Still further, the cream acts to overcome erectile dysfunction in males causing restoration of natural sexual function. These applications and others share as a common mechanism of action, improvement in local blood flow.
  • L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive
  • other agents could be used which are also precursors or donors of nitric oxide.
  • Pharmaceutically acceptable salts include hydrochloride, glutamate, butyrate, and glycolate.
  • a variety of means for effecting or improving absorption of the active agent can be envisioned.
  • One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt.
  • biophysically hostile environments include but are not limited to; high ionic strength by the addition of ionic salts such as sodium chloride, magnesium chloride or choline chloride; high or low pH by adding pharmaceutically acceptable acids or bases; and highly hydrophobic environments by decreasing water content and increasing lipid, oil and/or wax content.
  • Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane.
  • Examples of neutralization of charge include delivery of the active agent in the form or an ester or salt such as arginine glutamate which is electronically neutral.
  • the agent was added to an appropriate preparation.
  • ions such as but not limited to sodium chloride, potassium chloride, choline chloride, magnesium chloride, lithium chloride, alone or in combination were added in high concentration.
  • Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment.
  • a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constituents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.
  • a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v).
  • the cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.
  • agents which when applied to scalp lacking sufficient hair causes hair growth through utilization of one of the body's own mechanisms.
  • This effect is achieved by providing the biochemical substrate at the local site from which nitric oxide is produced.
  • Nitric oxide causes increased local blood flow, which enables the growth of hair.
  • agents which when applied to leg ulcers cause healing through use of the body's own mechanisms.
  • agents that when applied to a penis subject to erectile dysfunction causes restoration of normal sexual function. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced.
  • Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site.

Abstract

A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation when applied nightly to scalp tissue lacking sufficient hair for a period of time causes substantial growth of hair on the scalp. Further, when applied to the penis of a subject with erectile dysfunction causes restoration of normal sexual function.

Description

    BACKGROUND
  • 1. Field of the Invention
  • This invention relates to topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
  • 2. Prior Art
  • Approaches to improving local blood flow have been many and consist of both systemic and topical approaches. Many beneficial effects could be obtained should improvement in local blood flow be achieved since impairment of local blood flow causes a variety of negative consequences.
  • It has been recognized that deficiencies in blood flow in the scalp occur in male pattern baldness. See G. Duplechain et al., J. Louisiana State Med Soc. 146, 7 (1994); P Klemp et al., J Invests Dermatol 95, 725 (1989); S Toshitani et al., J Dermatol 17, 240 (1990). Topical minoxidil has been used as an agent for hair growth in male pattern baldness with varying results. Though the suggestion has been made that minoxidil operates through increase in the blood supply to the scalp, many investigators have failed to show such an effect. See E de Boer et al., Acta Dermato-Venereoligica 68, 271 (1988); C Bunker et al., British J Derm 117, 668 (1987).
  • It has long been recognized that impaired blood flow to the penis is a major cause of erectile failure (impotence) in men. See A Moradian et al. Am J. Med 85, 748, (1988); T Hwang et al. J Formosan Med Assoc 89, 992 (1990). Further it has been recognized by using isolated tissue in vitro and in animal experiments that nitric oxide is an important mediator of relaxation of the vessels in penile cavernous tissue. See H Kirkeby et al. Acta Physiol Scand 149, 385 (1993). Topical nitroglycerine has been used in the treatment of impotence because of its ability to dilate vessels. The results were inconclusive and the treatment not well tolerated because of the cardiac response to nitroglycerine. See S Negelev J Urology 143, 586 (1990).
  • Accordingly, several objects and advantages of the instant invention are to induce the growth of hair on portions of human scalp which has insufficient hair by means of enhancement of the body's natural mechanisms. It is yet another object of the instant invention to induce healing of superficial ulcers of the limbs by means of enhancement of the body's natural mechanisms. It is still another object of the instant invention to overcome erectile failure restoring natural male sexual function by means of enhancement of the body's own natural mechanisms.
  • SUMMARY OF THE INVENTION
  • It was discovered that topical application of a nitric oxide precursor, L-arginine, in its various forms contained in a variety of topical preparations, either by themselves or with other agents to aid in penetration, such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to the scalp causes hair growth, when administered to superficial ulcers causes healing and when administered to the penis enhances erectile function.
  • In one embodiment of the invention, a penetrating cream containing L-arginine at an effective concentration and a salt, such as sodium chloride, at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to nightly to the scalp containing a deficit of hair induces hair growth within 3-4 months.
  • Further, in accordance with this invention, a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to the penis induces firm and natural erections within 20 minutes.
  • Consequently, with the discovery of the present invention, a means to restore hair growth on a portion of scalp scarce in hair has been found. Further, with the discovery of the present invention, a means to heal superficial ulcers has been found. Additionally, with the discovery of the present invention, a means to overcome erectile dysfunction has been found.
  • In preferred embodiments, the delivery vehicle is a penetrating cream, the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption.
  • These and other objects and features of the present invention will become apparent to those skilled in the art from reading the description of the invention, which follows.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The preferred embodiment consists of a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (12.5% w/v), choline chloride (10%), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The components of the base cream may be those commonly found in hand creams, such as water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A & D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, and BHA. L-arginine hydrochloride provides a precursor to the molecule, nitric oxide, NO. Nitric oxide is the substance that relaxes the blood vessels, allowing for increased blood flow. Choline chloride, sodium chloride and magnesium chloride provides a high ionic strength environment for the highly charged molecule, L-arginine. This high ionic strength environment is an example of a hostile biophysical environment for L-arginine. That is, the highly charged ionic strength is an unfavorable environment for the highly charged L-arginine making the L-arginine anxious to move to a more hospitable, less charged environment such as human tissue. The base cream containing L-arginine, choline chloride, sodium chloride and magnesium chloride is the agent which produces beneficial effects such as hair growth, healing of ulcers such as leg ulcers or restoration of normal erectile function in males suffering from erectile dysfunction.
  • The cream acts effectively to induce hair growth on human scalp lacking sufficient hair when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. Yet further, the cream acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Still further, the cream acts to overcome erectile dysfunction in males causing restoration of natural sexual function. These applications and others share as a common mechanism of action, improvement in local blood flow.
  • OTHER EMBODIMENTS
  • Other Active Agents
  • While L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive, other agents could be used which are also precursors or donors of nitric oxide. These include D,L-arginine, L-arginine, alkyl (ethyl, methyl, propyl, isopropyl, butyl, isobutyl, t-butyl) esters of L-arginine and salts thereof. Pharmaceutically acceptable salts include hydrochloride, glutamate, butyrate, and glycolate.
  • In the case of an alternative active agent were used it would be simply substituted for L-arginine in a delivery preparation and the preparation used as in the case of the L-arginine preparation.
  • Other Means of Effecting or Improving Absorption
  • A variety of means for effecting or improving absorption of the active agent can be envisioned. One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt. Examples of biophysically hostile environments, include but are not limited to; high ionic strength by the addition of ionic salts such as sodium chloride, magnesium chloride or choline chloride; high or low pH by adding pharmaceutically acceptable acids or bases; and highly hydrophobic environments by decreasing water content and increasing lipid, oil and/or wax content. Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane. Examples of neutralization of charge include delivery of the active agent in the form or an ester or salt such as arginine glutamate which is electronically neutral.
  • In each case of creating a hostile biophysical environment for the active agent, the agent was added to an appropriate preparation. In the case of creating a high ionic strength ions such as but not limited to sodium chloride, potassium chloride, choline chloride, magnesium chloride, lithium chloride, alone or in combination were added in high concentration. Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment. Alternatively a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constituents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.
  • EXAMPLE 1
  • In this example a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.
  • EXAMPLE 2
  • In a 54 year old man with a history of impotence twice daily administration of a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (10% w/v) and magnesium chloride (5% w/v) directly to the penis twice daily for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment daily.
  • EXAMPLE 3
  • In a 62 year old man with a history of impotence placed a condom containing a water based penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v) was worn on the flaccid penis for 30-60 minutes before erection was desired. At that time, when sexual performance was needed, an erection was easily obtained and normal sexual activity was conducted.
  • Accordingly, it can be seen that in the present invention I have provided agents, which when applied to scalp lacking sufficient hair causes hair growth through utilization of one of the body's own mechanisms. This effect is achieved by providing the biochemical substrate at the local site from which nitric oxide is produced. Nitric oxide causes increased local blood flow, which enables the growth of hair. Further I have provided agents which when applied to leg ulcers cause healing through use of the body's own mechanisms. Still further I have provided agents that when applied to a penis subject to erectile dysfunction causes restoration of normal sexual function. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced. Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site.
  • Although the description above contains many specificities, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of this invention. Various other embodiments and ramifications are possible within this scope.
  • Thus the scope of the invention should be determined by the appended claims and their legal equivalents, rather than by the examples given.

Claims (13)

1-32. (canceled)
33. An article, comprising:
a trans-dermal patch comprising an environment comprising one or more ionic salts together at a concentration higher than the concentration of ionic salts in human skin.
34. The article of claim 33, wherein the one or more ionic salts comprises sodium chloride.
35. The article of claim 33, wherein the one or more ionic salts comprises magnesium chloride.
36. The article of claim 33, wherein the one or more ionic salts comprises choline chloride.
37. The article of claim 33, wherein the trans-dermal patch further comprises L-arginine.
38. The article of claim 37, wherein the environment causes the L-arginine to migrate from the patch into the skin once the patch is applied to the skin.
39. The article of claim 33, wherein the trans-dermal patch further comprises an L-arginine salt.
40. The article of claim 39, wherein the L-arginine salt comprises L-arginine hydrochloride.
41. The article of claim 39, wherein the environment causes the L-arginine salt to migrate from the patch into the skin once the patch is applied to the skin.
42. The article of claim 33, wherein the trans-dermal patch further comprises a penetrating agent.
43. A method, comprising applying the trans-dermal patch of claim 33 to the skin of a subject.
44. The method of claim 43, wherein the subject is a human.
US14/067,219 1997-09-17 2013-10-30 Topical delivery of l-arginine to cause beneficial effects Abandoned US20140066511A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/067,219 US20140066511A1 (en) 1997-09-17 2013-10-30 Topical delivery of l-arginine to cause beneficial effects

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/932,227 US7914814B2 (en) 1997-09-17 1997-09-17 Topical delivery of arginine of cause beneficial effects
US12/833,874 US8603519B2 (en) 1997-09-17 2010-07-09 Topical delivery of L-arginine to cause beneficial effects
US14/067,219 US20140066511A1 (en) 1997-09-17 2013-10-30 Topical delivery of l-arginine to cause beneficial effects

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/833,874 Continuation US8603519B2 (en) 1997-09-17 2010-07-09 Topical delivery of L-arginine to cause beneficial effects

Publications (1)

Publication Number Publication Date
US20140066511A1 true US20140066511A1 (en) 2014-03-06

Family

ID=25461979

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/932,227 Expired - Fee Related US7914814B2 (en) 1997-09-17 1997-09-17 Topical delivery of arginine of cause beneficial effects
US12/833,874 Expired - Fee Related US8603519B2 (en) 1997-09-17 2010-07-09 Topical delivery of L-arginine to cause beneficial effects
US14/067,219 Abandoned US20140066511A1 (en) 1997-09-17 2013-10-30 Topical delivery of l-arginine to cause beneficial effects
US14/072,008 Abandoned US20140072618A1 (en) 1997-09-17 2013-11-05 Topical delivery of l-arginine to cause beneficial effects

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/932,227 Expired - Fee Related US7914814B2 (en) 1997-09-17 1997-09-17 Topical delivery of arginine of cause beneficial effects
US12/833,874 Expired - Fee Related US8603519B2 (en) 1997-09-17 2010-07-09 Topical delivery of L-arginine to cause beneficial effects

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/072,008 Abandoned US20140072618A1 (en) 1997-09-17 2013-11-05 Topical delivery of l-arginine to cause beneficial effects

Country Status (1)

Country Link
US (4) US7914814B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280984A1 (en) * 2004-04-19 2008-11-13 Strategic Science & Technologies, Llc Transdermal Delivery of Beneficial Substances Effected By a Hostile Biophysical Environment
US20100317737A1 (en) * 1997-09-17 2010-12-16 Strategic Science & Technologies, Llc Topical delivery of l-arginine to cause beneficial effects
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US9155701B2 (en) 2009-06-24 2015-10-13 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2835840C (en) 2004-04-19 2016-06-14 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
HUP0401422A2 (en) 2004-07-15 2006-04-28 G Laszlo Meszaros Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
US8445536B2 (en) * 2005-03-31 2013-05-21 Ajinomoto Co., Inc. Arginine-containing compositions and methods for increasing blood flow using same
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
WO2011011808A1 (en) * 2009-07-30 2011-02-03 Roman Buga A cosmetic composition comprising sodium chloride in combination with one or more of protein, collagen, gelatin or amino acid
WO2011075655A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
EP2968124A1 (en) 2013-03-15 2016-01-20 Strategic Science & Technologies, LLC Transdermal formulations of fluticasone
JP2016513690A (en) 2013-03-15 2016-05-16 ストラテジック サイエンス アンド テクノロジーズ, エルエルシー Transdermal delivery of sildenafil and other phosphodiesterase 5 inhibitors
WO2016112201A1 (en) 2015-01-07 2016-07-14 Strategic Science & Technologies, Llc Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications
US20170135969A1 (en) * 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2018045244A1 (en) 2016-09-01 2018-03-08 Jds Therapeutics, Llc Magnesium biotinate compositions and methods of use
KR20210110572A (en) 2018-11-02 2021-09-08 뉴트리션 21, 엘엘씨 Composition Containing Inositol Stabilized Arginine Silicate Complex and Inositol for Improving Cognitive Function of Video Gamers
WO2021127048A1 (en) 2019-12-16 2021-06-24 Nutrition 21, Llc Methods of production of arginine-silicate complexes

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5940E (en) 1906-01-30 1906-07-27 Ramier Et Mauberque Soc Radiator
FR5940M (en) 1966-10-18 1968-04-08
FR1553063A (en) 1967-11-28 1969-01-10
US3960782A (en) * 1974-09-27 1976-06-01 The Procter & Gamble Company Shampoo compositions which impart high luster and manageability to hair
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4102995A (en) * 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
GB2094142B (en) 1981-03-06 1984-09-26 Lab For Applied Biology Ltd Injectable solution containing theophylline and a basic amino acid
GB2126868B (en) 1982-09-20 1986-03-19 Ralston Purina Co Method of improving the shelf life of processed meat products
US4702903A (en) * 1983-10-03 1987-10-27 Keefer Bowie Method and apparatus for gas separation and synthesis
FR2557452B1 (en) * 1983-12-28 1986-08-14 Roussel Uclaf NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4722837A (en) * 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
JPS61122222A (en) * 1984-11-19 1986-06-10 Koken:Kk Hemostatic agent composed of collagen or gelatin and protamine
US4732892A (en) * 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
GB8606368D0 (en) * 1986-03-14 1986-04-23 Unilever Plc Skin treatment composition
FR2602678B1 (en) 1986-08-13 1992-06-05 Drouault Guy AQUEOUS PHARMACEUTICAL COMPOSITION BASED ON MAGNESIUM, SODIUM AND POTASSIUM SALTS FOR THE REGULATION OF LOCAL CIRCULATIONS
US5030427A (en) * 1986-12-04 1991-07-09 Monsanto Company Gallium purification
US4885157A (en) 1987-02-13 1989-12-05 Fiaschetti Mary G Dermal cosmetic composition and applications therefor
DE3715576A1 (en) * 1987-05-09 1988-11-24 Wella Ag NEW MACROMOLECULAR, SURFACE-ACTIVE, QUATERNAIRE N-SUBSTITUTED CHITOSAN DERIVATIVES AND COSMETIC AGENT BASED ON THESE NEW CHITOSAN DERIVATIVES
US5925372A (en) * 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
GB2217595B (en) 1988-04-21 1991-11-20 American Cyanamid Co Antiinflammatory gel
US4891404A (en) * 1988-05-27 1990-01-02 Purdue Research Foundation Biodegradable graft copolymers
DE3827362A1 (en) * 1988-08-12 1990-02-15 Basf Ag POWDERY, HYDROPHILE THEOPHYLINE FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
AU4345489A (en) * 1988-09-30 1990-04-18 Duane R. Schultz Anti-inflammatory and analgesic compounds, related compositions and methods for preparation and use thereof
US4945901A (en) * 1989-03-22 1990-08-07 Burcke Jr Harry J Hand therapy apparatus and method therefor
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5476852A (en) * 1989-05-03 1995-12-19 Janssen Pharmaceutica N.V. Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
ATE128452T1 (en) 1989-10-17 1995-10-15 Merck & Co Inc S(+)-IBUPROFEN-L-AMINO ACID AND S(+)-IBUPROFEN-D-AMINO ACID AS ANALGESICS WITH GREATER PHARMACOLOGICAL POTENTIAL.
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
JPH045231A (en) 1990-04-20 1992-01-09 Morishita Pharmaceut Co Ltd Analgesic for chronic pain
US5332758A (en) * 1990-07-13 1994-07-26 Kanebo, Ltd. Collagen metabolism ameliorant and its use
US5824658A (en) 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
AU651630B2 (en) 1990-11-14 1994-07-28 Pharmacia & Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds
DE4100975A1 (en) * 1991-01-15 1992-07-16 Weuffen Wolfgang Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth
US5210099A (en) * 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
CA2105313A1 (en) * 1991-03-01 1992-09-02 Rafael Abad Therapeutic and cosmetic compositions for treatment of skin
WO1992015276A2 (en) 1991-03-01 1992-09-17 Mcginnis, Michael Therapeutic and cosmetic compositions for treatment of skin
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
TW197374B (en) 1991-05-27 1993-01-01 Fujisawa Pharmaceutical Co
JP2636118B2 (en) * 1991-09-10 1997-07-30 三省製薬株式会社 Hair restorer
US5254331A (en) * 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5217652A (en) * 1991-10-04 1993-06-08 The Gillette Company Conditioning shampoo
EP0552879B1 (en) * 1992-01-21 1998-08-19 Macrochem Corporation Improved iontophoretic administration of drugs
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
KR100271225B1 (en) 1992-08-31 2000-11-01 후나키 토시유키 Safety switch assembly
GB9222772D0 (en) 1992-10-30 1992-12-09 Unilever Plc Cosmetic composition
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
JP3191833B2 (en) 1993-02-24 2001-07-23 三菱東京製薬株式会社 Hair restorer
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5852058A (en) 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
JP3200723B2 (en) 1993-08-18 2001-08-20 日本農薬株式会社 Hair restorer
DE4338793A1 (en) 1993-11-12 1995-05-18 Froelich Juergen C L-arginine and analogues as platelet aggregation inhibitors
DE4341000A1 (en) 1993-12-02 1995-06-08 Beiersdorf Ag Use of L-arginine, L-ornithine or L-citrulline and topical preparations with these substances
US5714472A (en) * 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
GB9409281D0 (en) * 1994-05-10 1994-06-29 Svedman Paul Transdermal device
GB9409768D0 (en) * 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US6190704B1 (en) 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
US5594032A (en) 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5853768A (en) * 1995-03-01 1998-12-29 Altadonna; James Topical preparation and method for pain relief
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5698738A (en) * 1995-05-15 1997-12-16 Board Of Regents, The University Of Texas System N-nitroso-N-substituted hydroxylamines as nitric oxide donors
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5645859A (en) * 1995-10-02 1997-07-08 Isp Investments Inc. Process for producing an alpha or beta-hydroxy acid-vinylpyrrolidone polymer, copolymer or graft polymer complex in the form of free-flowing powders having a high acid loading
US5605685A (en) * 1995-09-13 1997-02-25 Isp Investments Inc. Non-irritating skin and hair rejuvenating compostion having a pH between 1 and 6.5
US5734080A (en) 1995-09-22 1998-03-31 Anihealth Corporation Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
FR2740339B1 (en) * 1995-10-26 1997-12-05 Oreal USE OF AT LEAST ONE NO-SYNTHASE INHIBITOR IN THE TREATMENT OF SENSITIVE SKIN
FR2740453B1 (en) 1995-10-27 1998-01-16 Bieurope PEPTIDE MIXTURES, THEIR PREPARATION AND COSMETIC COMPOSITIONS CONTAINING THEM
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
JP4020989B2 (en) 1996-03-06 2007-12-12 株式会社ノエビア Blood flow promoting agent and external preparation for skin comprising the same
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
FR2762782B1 (en) * 1997-05-05 1999-06-11 Oreal COMPOSITION COMPRISING A MICROORGANISM CULTURE MEDIUM AND USE THEREOF
ATE499343T1 (en) * 1997-07-03 2011-03-15 Us Gov Health & Human Serv NITROGEN OXIDE RELEASE AMIDINE AND ENAMINE RELATED DIAZENIUM DIOLATES, PREPARATIONS AND USES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US5922332A (en) * 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US5895658A (en) * 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
EP2158907B1 (en) 1997-09-17 2015-08-05 Strategic Science & Technologies, LLC Topical administration of arginine for pain treatment
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US5906822A (en) * 1997-09-25 1999-05-25 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
CA2333903A1 (en) * 1998-06-01 1999-12-09 Anthony J. Verbiscar Topical transdermal treatments
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
AU4972599A (en) * 1998-07-07 2000-01-24 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
DE19831798A1 (en) 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement
AR043078A1 (en) * 1998-09-14 2005-07-20 Dow Agrosciences Llc PROCESSES TO PREPARE CARBOXYL ACIDS
JP2002528400A (en) * 1998-10-26 2002-09-03 ユニバーシティー オブ マサチューセッツ Skin treatment with adenosine or adenosine analogues
US6261594B1 (en) * 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
JP2000186028A (en) 1998-12-21 2000-07-04 Nobuko Koga Cosmetic
FR2787996B1 (en) 1998-12-30 2002-05-10 Dior Christian Parfums COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AN ACTIVE INGREDIENT THAT STIMULATES THE SYNTHESIS OF HSP 32 PROTEIN IN THE SKIN AND COSMETIC PROCESSING METHOD
DE60029569T2 (en) * 1999-03-12 2007-07-26 Mystic Tan, Inc., Carollton BENDING DEVICE FOR ELECTROSTATIC APPLICATION OF COATING MATERIALS ON THE SKIN
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6375672B1 (en) * 1999-03-22 2002-04-23 Board Of Trustees Of Michigan State University Method for controlling the chemical and heat induced responses of collagenous materials
FR2794974B1 (en) * 1999-06-16 2001-08-17 Exsymol Sa COSMETIC COMPOSITION FOR SLIMMING BASED ON L-ARGININE, AN ANALOG OF L-ARGININE OR A DERIVATIVE THEREOF, APPLICABLE TOPICALLY
EP1210933A4 (en) 1999-09-07 2003-01-22 Soken Kk Skin normalizing agents
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6719997B2 (en) * 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6602912B2 (en) * 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6565879B1 (en) * 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
FR2802414B1 (en) 1999-12-20 2003-06-27 G Pharm Lab COMPOSITION, ESPECIALLY COSMETIC OR DERMATOLOGICAL, CONTAINING OLIGOSACCHARIDES, METHOD FOR THE PREPARATION THEREOF AND METHOD FOR THE COSMETIC TREATMENT
JP2001288068A (en) 2000-04-06 2001-10-16 Nof Corp Skin cosmetic
FR2810540B1 (en) 2000-06-21 2004-04-30 C3D NEW COSMETIC OR HYGIENIC PREPARATIONS IN THE FORM OF DISPERSION
JP2002003373A (en) 2000-06-27 2002-01-09 Shiseido Co Ltd Skin care preparation
FR2811995B1 (en) * 2000-07-21 2003-06-06 Oreal POLYMER COMPRISING WATER-SOLUBLE UNITS AND LCST UNITS, AND AQUEOUS COMPOSITION COMPRISING SAME
US6538033B2 (en) * 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
JP2004520388A (en) * 2001-01-25 2004-07-08 ザ ジェネラル ホスピタル コーポレーション NOS inhibitors for treating wrinkles
DE10128910A1 (en) 2001-06-15 2002-12-19 Beiersdorf Ag Combination of arginine and ascorbic acid is used in the production of cosmetic or dermatological compositions for tightening and/or strengthening the skin, especially in cellulite treatment
US20030157185A1 (en) * 2002-02-08 2003-08-21 Lou Paradise Topical treatment of neuropathy
CN100430399C (en) 2002-03-20 2008-11-05 昆士兰大学 Methods and compositions comprising nitric oxide donors and opioid analgesics
JP4885424B2 (en) 2002-03-22 2012-02-29 メルク セロノ ソシエテ アノニム Use of IL-18 inhibitors for the treatment and / or prevention of peripheral vascular disease
JP2003286129A (en) 2002-03-27 2003-10-07 Hakugen:Kk Slimming sheet material
EP1497268A4 (en) 2002-04-05 2006-01-18 Nitromed Inc Nitric oxide donors, compositions and methods of use
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
EP1625844A4 (en) * 2003-05-16 2009-05-13 Lotus Pharmaceutical Co Ltd The composition for external use by percutaneous administration
AU2003903037A0 (en) * 2003-06-17 2003-07-03 Institute Of Nutraceutical Research Connective tissue derived polypeptides
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
JP2005200370A (en) 2004-01-16 2005-07-28 Nikko Chemical Co Ltd Nitrogen monoxide production promotor and its utilization
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102282A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
WO2006096360A1 (en) 2005-03-03 2006-09-14 Isw Group, Inc. Topical gels compositions
US7442690B2 (en) * 2005-03-14 2008-10-28 P & L Enterprise Llc Topical treatment for psoriasis
WO2006133107A2 (en) * 2005-06-03 2006-12-14 The Texas A & M University System Specific binding sites in collagen for integrins and use thereof
EP1770086A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Selected CGRP antagonists, process for their preparation as well as their use as medicaments
EP2054425A1 (en) * 2006-08-11 2009-05-06 The University Of Warwick Osmium compounds
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
US20100260739A1 (en) * 2009-03-09 2010-10-14 Bioatla, Llc Mirac Proteins
EP2445493A1 (en) * 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
BRPI0925099A2 (en) * 2009-06-24 2018-10-16 Strategic Science & Tech Llc topical composition containing ibuprofen

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317737A1 (en) * 1997-09-17 2010-12-16 Strategic Science & Technologies, Llc Topical delivery of l-arginine to cause beneficial effects
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9050365B2 (en) 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20080280984A1 (en) * 2004-04-19 2008-11-13 Strategic Science & Technologies, Llc Transdermal Delivery of Beneficial Substances Effected By a Hostile Biophysical Environment
US9457092B2 (en) 2009-06-24 2016-10-04 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US10682357B2 (en) 2009-06-24 2020-06-16 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9155701B2 (en) 2009-06-24 2015-10-13 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9492458B2 (en) 2009-06-24 2016-11-15 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9161915B2 (en) 2009-06-24 2015-10-20 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US9675619B2 (en) 2009-06-24 2017-06-13 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9737543B2 (en) 2009-06-24 2017-08-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10898489B2 (en) 2009-06-24 2021-01-26 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10172865B2 (en) 2009-06-24 2019-01-08 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9498482B2 (en) 2010-12-29 2016-11-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9833456B2 (en) 2010-12-29 2017-12-05 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications

Also Published As

Publication number Publication date
US20020041903A1 (en) 2002-04-11
US20100291195A1 (en) 2010-11-18
US20140072618A1 (en) 2014-03-13
US7914814B2 (en) 2011-03-29
US8603519B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
US8603519B2 (en) Topical delivery of L-arginine to cause beneficial effects
US7629384B2 (en) Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) Topical and oral delivery of arginine to cause beneficial effects
AU737199B2 (en) A delivery of arginine to cause beneficial effects
US5895658A (en) Topical delivery of L-arginine to cause tissue warming
US5922332A (en) Topical delivery of arginine to overcome pain
EP1732577B1 (en) Topical delivery of l-arginine to improve body and skin appearance
EP0414605B1 (en) Pasty aqueous pharmaceutical compositions
EP1317309B1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
JP2002515401A5 (en)
JP2001064147A (en) Skin cosmetic for slimming
JPH0812531A (en) Trichogen and depilatory compound with lipid extracted from coix seed
JPH0687723A (en) Hair tonic liquid and its production
JP3909008B2 (en) Keratinase inhibitor and skin external preparation containing the same
US20230355500A1 (en) Topical composition
JPH1129461A (en) Skin cosmetic containing hydroxyaspartic acid

Legal Events

Date Code Title Description
AS Assignment

Owner name: STRATEGIC SCIENCE & TECHNOLOGIES, LLC, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOSSEL, ERIC THOR;REEL/FRAME:031552/0803

Effective date: 20050614

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION